Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 2 2Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 6Breast 4Other 3Thoracic 2Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Head & Neck 2Gynecologic 2CNS 2Sarcoma 1Myeloid 1

Conditions

Brain Neoplasms 592Glioblastoma 572Glioma 298Central Nervous System Neoplasms 208Gliosarcoma 177Neuroblastoma 175Astrocytoma 174Oligodendroglioma 112Carcinoma, Non-Small-Cell Lung 92Medulloblastoma 80Breast Neoplasms 74Ependymoma 61Sarcoma 60Meningioma 60Neoplasm Metastasis 57Melanoma 56Recurrence 55Neoplasms 51Lung Neoplasms 48Neurofibromatosis 1 43Meningeal Carcinomatosis 40Osteosarcoma 39Pheochromocytoma 38Rhabdomyosarcoma 37Wilms Tumor 36Paraganglioma 35Lymphoma, Non-Hodgkin 32Neuroectodermal Tumors, Primitive, Peripheral 29Lymphoma 27Sarcoma, Ewing 26

Interventions

Ondansetron 2rolapitant 1Aprepitant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Nausea × CNS × Clear all
NCT02991456 2023-07-11

Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide

Duke University

Phase 2 Completed
48 enrolled 25 charts
CNS

Glioma, Nausea, Vomiting

NCT01450826 2018-06-26

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Duke University

Phase 2 Completed
136 enrolled 10 charts
CNS

Glioma, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡